Next-Generation-Sequencing Approach to Neutropenic Sepsis
ConditionFebrile Neutropenia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBoris Böll
About this trial
The aim of this prospective, observational, non-interventional, multi-centre study of the diagnostic use of DISQVER in neutropenic patients with FN is to provide further evidence of the efficacy of an NGS-based approach for detecting bloodstream infection in neutropenic patients.
Eligibility criteria
Qualifiers
Age ≥18 years
Informed consent
Neutropenia defined as <500 ANC (Absolute neutrophil Count)/µl or <1000 WBC (White bloddcell Count)/µl if ANC is not available
Fever (with an onset < 24h) or Sepsis (with an onset <24h) Patients with a life-threatening - organ dysfunction caused by a dysregulated host response to a suspected or proven infection.
Disqualifiers
Age < 18 years
Refusal or inability to give consent Inability to give informed consent if no acceptable patient representative is available
Patients who had previously been included, but develop a new episode of fever during the same hospitalization, will not be included a second time
Death is deemed imminent and inevitable
Trial design
Treatments tested in this trial
- DISQVER
Treatment groups
No treatment groups listed
Locations
6University Hospital of Cologne Cologne Germany
Hospital Dessau06847, Dessau Germany
University Hospital of Essen45147, Essen Germany
University Hospital of Frankfurt60590, Frankfurt am Main Germany
Sponsors and collaborators
Boris Böll
Lead sponsor
University Hospital of Cologne
Sponsor institution
Noscendo GmbH
Collaborator
Source ClinicalTrials.gov